Adult Immunization

Latest News

Abrysvo Efficacy Sustained in Older Adults Through Second RSV Season /image credit Pfizer logo: ©Kathy Images stock.adobe.com
Abrysvo Efficacy Sustained in Older Adults Through Second RSV Season

March 1st 2024

The bivalent vaccine demonstrated "durable efficacy" of more than 80% over 2 RSV seasons, according to Pfizer's report of topline findings from the RENOIR trial.

ACIP Recommends Monovalent COVID-19 Booster for Older Adults this Spring
ACIP Recommends Monovalent COVID-19 Booster for Older Adults this Spring

February 29th 2024

Of Vaccine Efficacy and COVID-19 Variants: 4 Questions / image credit ©coronavirus evolution: PX Media/stock.adobe.com
Of Vaccine Efficacy and COVID-19 Variants: 4 Questions

February 16th 2024

GSK RSV Vaccine Arexvy Under FDA Priority Review for Prevention of RSV in High-Risk Adults Aged 50 to 59 Years / image credit GSK logo: ©desertlands/stock.adobe.com
GSK RSV Vaccine Arexvy Under FDA Priority Review for Prevention of RSV in High-Risk Adults Aged 50 to 59 Years

February 8th 2024

Two RSV Vaccines, One Savvy Patient who Asks, "Which One do You Recommend?" /  image credit vaccine vials ©Sherry Young/stock.adobe.com
Two RSV Vaccines, One Savvy Patient who Asks, "Which One do You Recommend?"

January 12th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.